Ernst Geutjes

Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing.

Develops therapeutic products intended to treat solid tumors